Latest News

Latest News

Quicker FDA Approval of Cancer Drugs Not Tied to Clinical Benefit

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date June 29, 2022

The FDA tends to approve cancer drugs faster than other agencies, but there is no link between faster review and high clinical benefit.

Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma

By

Vicki Moore, PhD

Publish Date June 29, 2022

Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.

Factors ID’d in Time to Breast Biopsy by Race, Ethnicity

Publish Date June 29, 2022

White women were more likely than Asian, Black, and Hispanic women to have a biopsy within 30 days or 60 days of an abnormal result.

Geriatric Screening and CARG Toxicity Assessment Tools Predict Adverse Outcomes

By

Vicki Moore, PhD

Publish Date June 29, 2022

The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer.

In AIDS-Related Lymphoma, Outcomes Worse With Hypoalbuminemia

Publish Date June 29, 2022

Among patients with AIDS-related lymphoma, hypoalbuminemia is linked to worse overall survival and progression-free survival.

Women Remain Underrepresented in Clinical Trials

Publish Date June 29, 2022

Researchers found that women made up 41% of cancer trial participants but 51% of the cancer patient population.

COVID-19 mRNA Vaccines Linked to Higher Adverse Event Risk vs Traditional Vaccines

By

Colby Stong

Publish Date June 29, 2022

Although adverse events were more likely with mRNA-based COVID-19 vaccines, the benefits of mRNA vaccination exceeded the risks.

Men With Breast Cancer Present at Later Stage, Have Worse Prognosis Than Women

By

Leah Lawrence

Publish Date June 28, 2022

At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.

Induction Chemo Plus CRT More Effective Than CRT Alone in Nasopharyngeal Carcinoma

By

Leah Lawrence

Publish Date June 28, 2022

Induction chemotherapy was associated with improvements in disease-free, failure-free, relapse-free, and progression-free survival.

Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma

By

Vicki Moore, PhD

Publish Date June 28, 2022

Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.